Northland Capmk Brokers Increase Earnings Estimates for BLFS

BioLife Solutions, Inc. (NASDAQ:BLFS - Free Report) - Equities researchers at Northland Capmk upped their Q1 2025 EPS estimates for BioLife Solutions in a research report issued on Monday, March 3rd. Northland Capmk analyst C. Byrnes now anticipates that the medical equipment provider will post earnings per share of ($0.02) for the quarter, up from their previous forecast of ($0.03). The consensus estimate for BioLife Solutions' current full-year earnings is ($0.30) per share. Northland Capmk also issued estimates for BioLife Solutions' Q2 2025 earnings at ($0.01) EPS and FY2025 earnings at ($0.03) EPS.

BioLife Solutions (NASDAQ:BLFS - Get Free Report) last issued its quarterly earnings results on Monday, March 3rd. The medical equipment provider reported $0.26 earnings per share for the quarter, topping the consensus estimate of ($0.06) by $0.32. BioLife Solutions had a negative return on equity of 6.61% and a negative net margin of 38.98%. The firm had revenue of $22.71 million for the quarter, compared to the consensus estimate of $21.73 million. During the same period in the prior year, the business posted ($0.21) earnings per share.

Several other equities research analysts have also recently issued reports on BLFS. KeyCorp boosted their price objective on shares of BioLife Solutions from $30.00 to $33.00 and gave the company an "overweight" rating in a research report on Friday, December 13th. TD Cowen boosted their price target on BioLife Solutions from $28.00 to $31.00 and gave the company a "buy" rating in a report on Wednesday, November 13th. Benchmark restated a "buy" rating and set a $30.00 price objective on shares of BioLife Solutions in a report on Thursday, December 19th. HC Wainwright lifted their target price on BioLife Solutions from $27.00 to $30.00 and gave the company a "buy" rating in a research report on Thursday. Finally, Craig Hallum increased their price target on BioLife Solutions from $30.00 to $32.00 and gave the stock a "buy" rating in a research report on Wednesday, November 13th. One equities research analyst has rated the stock with a sell rating and seven have issued a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $29.86.

Remove Ads

BioLife Solutions Trading Down 3.8 %

Shares of BLFS traded down $0.97 during trading hours on Thursday, reaching $24.86. 648,726 shares of the company traded hands, compared to its average volume of 350,114. The stock's fifty day moving average price is $26.65 and its 200 day moving average price is $25.49. The company has a current ratio of 2.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.03. The firm has a market cap of $1.17 billion, a price-to-earnings ratio of -23.45 and a beta of 2.04. BioLife Solutions has a 12-month low of $14.84 and a 12-month high of $29.55.

Insider Buying and Selling at BioLife Solutions

In other BioLife Solutions news, CFO Troy Wichterman sold 987 shares of the firm's stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $27.02, for a total value of $26,668.74. Following the completion of the sale, the chief financial officer now directly owns 121,779 shares in the company, valued at $3,290,468.58. This trade represents a 0.80 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Aby J. Mathew sold 7,604 shares of the company's stock in a transaction on Monday, December 16th. The stock was sold at an average price of $27.33, for a total value of $207,817.32. Following the transaction, the executive vice president now directly owns 276,315 shares in the company, valued at approximately $7,551,688.95. The trade was a 2.68 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 11,978 shares of company stock worth $322,724 over the last quarter. Insiders own 2.20% of the company's stock.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Invesco Ltd. boosted its holdings in BioLife Solutions by 1.1% in the fourth quarter. Invesco Ltd. now owns 3,239,469 shares of the medical equipment provider's stock worth $84,097,000 after acquiring an additional 36,176 shares in the last quarter. Fred Alger Management LLC boosted its stake in BioLife Solutions by 1.0% in the 4th quarter. Fred Alger Management LLC now owns 1,594,221 shares of the medical equipment provider's stock worth $41,386,000 after purchasing an additional 16,274 shares in the last quarter. State Street Corp grew its position in BioLife Solutions by 7.3% during the 3rd quarter. State Street Corp now owns 1,412,316 shares of the medical equipment provider's stock worth $35,364,000 after purchasing an additional 95,788 shares during the last quarter. Millennium Management LLC grew its position in BioLife Solutions by 49.1% during the 4th quarter. Millennium Management LLC now owns 1,145,347 shares of the medical equipment provider's stock worth $29,733,000 after purchasing an additional 377,111 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its stake in BioLife Solutions by 4.8% during the 4th quarter. Dimensional Fund Advisors LP now owns 887,008 shares of the medical equipment provider's stock valued at $23,028,000 after purchasing an additional 40,416 shares in the last quarter. 93.24% of the stock is owned by institutional investors and hedge funds.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.